Drug search by name

Immune globulin intravenous and subcutaneous and Zoledronic Acid IV

Determining the interaction of Immune globulin intravenous and subcutaneous and Zoledronic Acid IV and the possibility of their joint administration.

Check result:

Immune globulin intravenous and subcutaneous <> Zoledronic Acid IV

Relevance: 25.04.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Immune globulin intravenous and subcutaneous may cause kidney problems, and combining it with other medications that can also affect the kidney such as zoledronic acid may increase that risk. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience symptoms that may suggest kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer. Immune globulin products, particularly those that contain sucrose as a stabilizer and administered at daily doses of 350 to 400 mg/kg or greater, have been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Factors predisposing to acute renal failure include any degree of preexisting renal insufficiency, age greater than 65 years, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and concomitant use of known nephrotoxic drugs.

MANAGEMENT: Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients. Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter. If renal function deteriorates, discontinuation of the product should be considered. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.

References

MMWR Morb Mortal Wkly Rep "Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm." ([1999 Jun 25]):
"Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises, Temecula, CA.
Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf." ([2002 Apr]):
Perazella MA "Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf." ([2009]):
Levy JB, Pusey EY "Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html." ([2000]):
Moses S "Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm." ([2011 Nov 25]):
"Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc, Gaithersburg, MD.
"Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation, Boca Raton, FL.
"Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring, King of Prussia, PA.
Naughton CA "Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html." ([2008]):
KDIGO. Kidney Disease Improving Global Outcomes "KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf." ([2012 Mar]):

Immune globulin intravenous and subcutaneous

Generic Name: immune globulin intravenous and subcutaneous

Brand name: Gammagard, Gammaked, Gamunex-C, Gammagard Liquid

Synonyms: Immune globulin (intravenous and subcutaneous)

What is Immune globulin intravenous and subcutaneous?

Zoledronic Acid IV

Generic Name: zoledronic acid

Brand name: Reclast, Zometa, Zometa Concentrate, Aclasta

Synonyms: Zoledronic acid, Zoledronic Acid

What is Zoledronic Acid IV?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions